Yunnan province boasts China’s richest biological resources, natural drugs, and ethnic medicine resources. With its advantageous location, resources, ethnic diversity, and ecology, the bio-pharmaceutical industry has become a key strategic emerging industry nurtured by Yunnan province.
The province has issued an action plan to develop the bio-pharmaceutical industry into one of its key industries. It aims to achieve a total operating income of 360 billion yuan and an added value of 110 billion yuan($15.09 billion) by 2024, making it an influential bio-pharmaceutical industry cluster in China.
In recent years, the bio-pharmaceutical industry in Yunnan has maintained a rapid development momentum. Yunnan has seized the strategic opportunities in the bio-products industry, such as vaccines and blood products, and has strengthened targeted investment in the industrial chain and promoted major project construction.
Starting from 2022, the Yunnan provincial government will allocate a special fund of 100 million yuan each year to support the development of the vaccine industry for three consecutive years.
With the continuous optimization of the bio-pharmaceutical environment, Yunnan vaccine companies are demonstrating their vitality, and their innovation abilities have been continuously improved.
The vaccine industry has become a leading and iconic industry in Yunnan’s bio-pharmaceutical sector. In 2022, five market entities in Yunnan engaged in the research, development, and production of human vaccines, with 14 varieties of vaccines on the market. The output value of the vaccine industry exceeded 10 billion yuan, reaching 11 billion yuan.
The vaccine industry is the most promising high-tech industry in the field of biotechnology. To further speed up the research, registration, production, and internationalization of vaccines in Yunnan, the provincial government has proposed specific measures in nine areas, including implementing a capacity-doubling plan and promoting the research and development of new vaccines.
It strives to build a complete vaccine industry chain, establish a vaccine industry cluster, and reach the leading level in vaccine research and development and production capacity nationwide by 2025.
The total economic output of the entire industry chain is expected to exceed 60 billion yuan, making the vaccine industry the main driving force behind the development of the bio-pharmaceutical industry.
In the future, Yunnan will continue to focus on three key areas: biotechnology drugs, modern traditional Chinese medicine, and health products. Efforts will be made to attract targeted investments, enhance innovation capabilities, establish industrial clusters, as well as develop a research, development, and production base for bio-pharmaceutical vaccines and modern traditional Chinese medicine, and a raw material base for natural drugs and health products.
